View Post

BARD1 Life Sciences (ASX:BD1) receives positive results from breast cancer study

In Clinical Studies News by Barbara Jacoby

By: Julia Seymour From: themarketherald.com BARD1 Life Sciences (BD1) has received results from a preliminary study demonstrating the feasibility of using SubB2M in an immunohistochemistry (IHC) application for breast cancer tissue The study compared cancer tissue from an invasive ductual breast cancer tumour biopsy to a non-cancer breast tissue biopsy The study also demonstrated that the SubB2M IHC test could …

View Post

Bard1 Life Sciences (ASX:BD1) reveals tech’s efficiency in detecting breast cancer

In Clinical Studies News by Barbara Jacoby

By: Samantha Goerling From: themarketherald.com.au Australian diagnostics company Bard1 Life Sciences (BD1) has revealed its SubB2M technology can detect all stages of breast cancer from a blood sample. Research completed by the Griffith University’s Institute for Glycomics found the technology could detect the cancer with 100 per cent specificity and 95 per cent sensitivity. “A non-invasive, accurate and reliable blood test …